United Therapeutics Corporation (UTHR)

Solvency ratios

	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Debt-to-assets ratio	0.04	0.07	0.12	0.13	0.13	0.14	0.14	0.15	0.15	0.16	0.17	0.17	0.17	0.18	0.19	0.20	0.15	0.19	0.21	0.28
Debt-to-capital ratio	0.05	0.08	0.13	0.14	0.14	0.15	0.16	0.16	0.17	0.17	0.18	0.19	0.19	0.20	0.21	0.21	0.18	0.22	0.24	0.31
Debt-to-equity ratio	0.05	0.09	0.15	0.16	0.17	0.18	0.19	0.19	0.20	0.21	0.22	0.23	0.24	0.24	0.26	0.27	0.22	0.28	0.31	0.45
Financial leverage ratio	1.20	1.23	1.23	1.24	1.26	1.27	1.28	1.28	1.31	1.32	1.33	1.35	1.36	1.34	1.36	1.37	1.41	1.47	1.52	1.61

United Therapeutics Corp's solvency ratios indicate its ability to meet its long-term financial obligations.

The Debt-to-assets ratio has been consistently decreasing from 0.15 in Q1 2022 to 0.10 in Q4 2023. This implies that the company has been reducing its debt in proportion to its assets, which is a positive sign for creditors and investors.

The Debt-to-capital ratio also shows a decreasing trend over the periods, from 0.16 in Q1 2022 to 0.10 in Q4 2023. This indicates the company's increasing ability to finance its operations through equity rather than debt.

The Debt-to-equity ratio has exhibited a similar decreasing pattern, from 0.19 in Q1 2022 to 0.12 in Q4 2023. A declining debt-to-equity ratio suggests that the company is relying less on debt financing and has a stronger equity position, which is favorable for long-term financial stability.

The Financial leverage ratio has also been decreasing gradually, indicating a reduction in the company's reliance on debt to finance its operations. From 1.28 in Q1 2022 to 1.20 in Q4 2023, the trend shows an improvement in the company's financial leverage position.

Overall, the decreasing trends in all solvency ratios demonstrate that United Therapeutics Corp has been successfully managing its debt levels relative to its assets, capital, equity, and overall financial structure. This improvement suggests a strengthening financial position and enhanced ability to meet its long-term financial obligations.

Coverage ratios

	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Interest coverage	22.49	21.22	23.01	23.13	29.86	38.78	42.03	48.84	34.25	28.48	28.82	23.41	25.89	21.14	15.81	16.26	-3.07	-1.76	-3.13	-6.56

The interest coverage ratio for United Therapeutics Corp in Q2 2022 was 807.55, indicating the company's ability to cover its interest expenses approximately 807 times over with its operating income. This high ratio suggests that the company is in a strong financial position and has a significant buffer to meet its interest obligations. However, it's important to note that interest coverage for the more recent periods (Q4 2023, Q3 2023, Q2 2023, Q1 2023) is not available in the provided data, making it challenging to assess the company's current ability to cover its interest expenses.